Taking a Look at the Data Behind Incyte Corporation (INCY)

Jefferies Group now has a “Buy” rating and a $148.00 target price on the stock. Credit Suisse Group AG’s price objective would suggest a potential upside of 18.01% from the stock’s current price.

Today, Jefferies Group LLC reiterated its Buy rating on Incyte (NASDAQ:INCY) with a price target of $148.00. Finally, TheStreet raised Incyte from a c rating to a b- rating in a report on Tuesday, February 14th. (JUNO) stock confirmed the flow of 1.96% with the final price of $25.00. Also, the current price highlights a discount of 147.93% to analysts’ high consensus price target.

Incyte Corporation has a consensus outperform rating from 21 Wall Street analysts, and the number of shares now sold short amount to at least 2.15% of shares outstanding.

Incyte Corporation shares increased 10.62 percent over the past week and rose 3.42 percent over the previous month.

A 52-week high/low is the highest and lowest price that a stock has traded at during the previous year.

The firm has a 50 day moving average price of $127.15 and a 200-day moving average price of $118.91.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Thursday, May 4th.

Earnings Per Share (EPS) is the earnings made by a company divided by their number of shares. Incyte had a return on equity of 50.38% and a net margin of 14.71%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Equities research analysts anticipate that Incyte will post ($0.77) earnings per share for the current fiscal year. If you are reading this report on another site, it was copied illegally and republished in violation of United States & worldwide copyright and trademark law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/credit-suisse-group-ag-reaffirms-outperform-rating-for-incyte-co-incy-updated.html. Their EPS should be compared to other companies in the Healthcare sector. The shares were purchased at an average cost of $124.26 per share, for a total transaction of $62,130.00.

Institutional Investors own 96.80% of Whole Foods Market, Inc. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul A. Friedman sold 50,000 shares of the company’s stock in a transaction dated Friday, March 17th.

Incyte Corporation (NASDAQ:INCY) is anticipated to report earnings of 159.70% per share for next year, according to research brokerages covering the stock. Following the completion of the transaction, the director now directly owns 302,976 shares of the company’s stock, valued at approximately $45,058,590.72. The disclosure for this sale can be found here. In the last three months, insiders have acquired 3,000 shares of company stock valued at $398,770 and have sold 137,968 shares valued at $19,395,245. The stock has been upbeat for quite some time as is up 89.29% for the last 20 trading days, and now the firm’s performance is turning out to be bullish with a 13.57% gain for the week.

Institutional investors have recently modified their holdings of the company. State Street Corp raised its position in Incyte by 110.7% in the first quarter. LLC now owns 1,104,616 shares of the biopharmaceutical company’s stock valued at $110,760,000 after buying an additional 90,098 shares during the period. Finally, Seven Bridges Advisors LLC boosted its stake in shares of Incyte by 27.1% in the third quarter. Shelton Capital Management now owns 3,595,000 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,583,388 shares during the period. Bank of Nova Scotia raised its position in shares of Incyte by 91.0% in the first quarter. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 965 shares in the last quarter. IFP Advisors Inc raised its position in shares of Incyte by 6.8% in the first quarter. Howard Hughes Medical Institute now owns 1,210 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 359 shares in the last quarter.

If you look at the company’s income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, INCY earned gross profit of 508.49 Million, in 2015 726.78 Million gross profit, while in 2016 Incyte Corporation (INCY) produced 1.06 Billion profit.

Leave a Reply

Your email address will not be published. Required fields are marked *